Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects With Multiple Sclerosis Who Have Completed Treatment in Study 205MS201 (SELECT)
Brief Summary: The primary objective of the study was to assess the safety and immunogenicity of extended treatment with DAC HYP. This evaluation included the following major components:

* An assessment of safety and immunogenicity of extended treatment with DAC HYP when administered to MS subjects who had completed 52 weeks of active therapy with DAC HYP in Study 201.
* An assessment of safety and immunogenicity during a 6-month washout period from DAC HYP.
* An assessment of safety and immunogenicity during reinitiation of therapy with DAC HYP after a 6-month washout period.
* An assessment of safety and immunogenicity of DAC HYP when administered to MS subjects who previously received placebo during Study 201.

The secondary objective is to assess the durability of the effect of DAC HYP on multiple sclerosis (MS) disease activity as measured by brain magnetic resonance imaging (MRI) scans and clinical MS relapses.


Options:
A: Arm Label: Teriflunomide 7 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Placebo / Teriflunomide 14 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Teriflunomide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo / Teriflunomide 14 mg | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Placebo / Teriflunomide 14 mg, Teriflunomide 14 mg / 14 mg, Teriflunomide 7 mg / 14 mg
B: Arm Label: Group 1: DAC HYP 150 mg; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Arm Label: Group 1: DAC HYP 300 mg; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Arm Label: Group 2: Washout then DAC HYP 150 mg; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process), Drug: Placebo | Arm Label: Group 2: DAC HYP 150 mg; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Arm Label: Group 3: Washout then DAC HYP 300 mg; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process), Drug: Placebo | Arm Label: Group 3: DAC HYP 300 mg; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab High Yield Process); Assigned to Arm(s): Group 1: DAC HYP 150 mg, Group 1: DAC HYP 300 mg, Group 2: DAC HYP 150 mg, Group 2: Washout then DAC HYP 150 mg, Group 3: DAC HYP 300 mg, Group 3: Washout then DAC HYP 300 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2: Washout then DAC HYP 150 mg, Group 3: Washout then DAC HYP 300 mg
C: Arm Label: Fingolimod (FTY720) 1.25 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo/Fingolimod (FTY720); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fingolimod (FTY720) 5.0 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): Fingolimod (FTY720) 1.25 mg/day, Fingolimod (FTY720) 5.0 mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Fingolimod (FTY720)
D: Arm Label: GA 40 mg / GA 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer acetate (GA) | Arm Label: Placebo / GA 40 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Glatiramer acetate (GA), Drug: Placebo | Intervention Type: DRUG; Name: Glatiramer acetate (GA); Assigned to Arm(s): GA 40 mg / GA 40 mg, Placebo / GA 40 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo / GA 40 mg

Answer: B